Predict your next investment

Corporation
santen.com

See what CB Insights has to offer

Investments

5

Portfolio Exits

2

Partners & Customers

10

Service Providers

1

About Santen Pharmaceutical

Santen carries out the research, development, sales, and marketing of pharmaceuticals. The company has its bases in about 20 countries and delivers products in more than 70 countries. In Japan, Santen holds the No. 1 share in the prescription ophthalmic pharmaceutical market. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.

Santen Pharmaceutical Headquarter Location

Grand Front Osaka Tower A 4-20 Ofuka-cho, Kita-ku

Osaka, 530-8552,

Japan

+81-6-6321-7000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Santen Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Santen Pharmaceutical in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Latest Santen Pharmaceutical News

Santen receives approval of Verkazia for VKC in China

May 11, 2022

Japanese ophthalmology specialist Santen Pharmaceutical (TYO: 4536) has received approval of Verkazia (ciclosporin eye drops) from the National Medical Products Administration (NMPA) in China through its Chinese legal entity for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged 4 years and above. The approval of Verkazia will provide more effective and safe choices for ophthalmologists in terms of VKC management… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Santen Pharmaceutical Investments

5 Investments

Santen Pharmaceutical has made 5 investments. Their latest investment was in International BioMedical Devices as part of their Convertible Note on August 8, 2016.

CBI Logo

Santen Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/30/2016

Convertible Note

International BioMedical Devices

$2.35M

Yes

1

11/12/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/30/2015

Series C

Subscribe to see more

$99M

Subscribe to see more

10

11/9/2014

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/2/2014

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/30/2016

11/12/2015

9/30/2015

11/9/2014

9/2/2014

Round

Convertible Note

Series B

Series C

Series A

Series B

Company

International BioMedical Devices

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.35M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Santen Pharmaceutical Portfolio Exits

2 Portfolio Exits

Santen Pharmaceutical has 2 portfolio exits. Their latest portfolio exit was RetroSense Therapeutics on September 06, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/6/2016

Acquired

$99M

1

6/2/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/6/2016

6/2/2016

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

1

10

Santen Pharmaceutical Acquisitions

3 Acquisitions

Santen Pharmaceutical acquired 3 companies. Their latest acquisition was Eyevance Pharmaceuticals on September 17, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/17/2020

Debt

$99M

$31.5M

Acquired

2

7/19/2016

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

9/23/2011

Subscribe to see more

$99M

Subscribe to see more

0

Date

9/17/2020

7/19/2016

9/23/2011

Investment Stage

Debt

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$31.5M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

10

0

Santen Pharmaceutical Partners & Customers

10 Partners and customers

Santen Pharmaceutical has 10 strategic partners and customers. Santen Pharmaceutical recently partnered with Aerie Pharmaceuticals on December 12, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

12/7/2021

Licensor

United States

Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions

Santen will also be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Roclanda ® .

4

8/10/2021

Licensee

United States

Santen and Sydnexis partner on childhood myopia treatment SYD-101

Santen and Sydnexis partner on childhood myopia treatment SYD-101

4

6/17/2021

Licensor

United States

Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan

Aerie and Santen announced an exclusive collaboration and license agreement for Rhopressa ® and Rocklatan ® in Japan and several other Asian countries in October 2020 .

3

5/18/2021

Licensee

United States

Subscribe to see more

Subscribe to see more

10

11/3/2020

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

12/7/2021

8/10/2021

6/17/2021

5/18/2021

11/3/2020

Type

Licensor

Licensee

Licensor

Licensee

Licensor

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions

Santen will also be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Roclanda ® .

Santen and Sydnexis partner on childhood myopia treatment SYD-101

Santen and Sydnexis partner on childhood myopia treatment SYD-101

Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan

Aerie and Santen announced an exclusive collaboration and license agreement for Rhopressa ® and Rocklatan ® in Japan and several other Asian countries in October 2020 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

4

3

10

10

Santen Pharmaceutical Service Providers

1 Service Provider

Santen Pharmaceutical has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Santen Pharmaceutical Team

1 Team Member

Santen Pharmaceutical has 1 team member, including former Chief Executive Officer, Jyrki Liljeroos.

Name

Work History

Title

Status

Jyrki Liljeroos

Chief Executive Officer

Former

Name

Jyrki Liljeroos

Work History

Title

Chief Executive Officer

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.